Librela is a monthly injection for dogs that controls pain from osteoarthritis. Approved by the FDA on May 5, 2023, it was the first monoclonal antibody drug approved for use in dogs. Unlike traditional painkillers, which work by reducing inflammation throughout the body, Librela targets a specific protein involved in pain signaling. It’s given as a shot under the skin at your veterinarian’s office once every four weeks.
How Librela Works
The active ingredient in Librela is bedinvetmab, a monoclonal antibody. That means it’s a lab-made protein designed to seek out and attach to one specific target in your dog’s body: a protein called nerve growth factor, or NGF. Dogs with osteoarthritis have elevated levels of NGF, and this protein plays a direct role in regulating pain. When bedinvetmab binds to NGF, it blocks the pain signal from reaching the brain.
This is a fundamentally different approach from anti-inflammatory painkillers like carprofen or meloxicam, which suppress inflammation broadly and can stress the liver, kidneys, and stomach lining over time. Monoclonal antibodies are barely processed by the liver and kidneys at all, which makes Librela a potential option for dogs who can’t tolerate traditional painkillers. That said, it hasn’t been specifically studied in dogs with acute or severe liver or kidney disease.
How Well It Works
In the pivotal U.S. clinical trial, 128 dogs received Librela and 131 received a placebo injection. Researchers measured success using a standardized pain questionnaire (the Canine Brief Pain Inventory), which scores both pain severity and how much pain interferes with daily activities on a 0 to 10 scale. A dog counted as a treatment success if its pain severity dropped by at least 1 point and its pain interference score dropped by at least 2 points.
At the 28-day mark, 47.4% of dogs on Librela met that success threshold, compared to 36.6% on placebo. That difference was statistically significant, and the improvement held at 42, 56, and 84 days. Those numbers mean Librela clearly outperforms placebo, but it also means roughly half of treated dogs didn’t meet the study’s threshold for meaningful improvement. Some dogs respond dramatically, while others see modest or no benefit. Most veterinarians recommend trying at least two or three monthly doses before deciding whether it’s working for your dog.
Dosing and Administration
The minimum dose is 0.5 mg per kilogram of body weight (0.23 mg per pound), given as a subcutaneous injection once a month. Your vet selects the appropriate vial size based on your dog’s weight. Dogs under 11 pounds receive a calculated dose drawn from a smaller-concentration vial. There are no pills to give at home; every dose is administered at the veterinary clinic.
Side Effects From Clinical Trials
Two large clinical trials, one in the U.S. and one in Europe, tracked side effects over 84 days in a total of roughly 550 dogs. In both studies, dogs receiving Librela experienced certain reactions at modestly higher rates than dogs receiving saline injections.
In the U.S. trial, the most common side effects were urinary tract infections (11.1% of Librela dogs vs. 8.0% on placebo), bacterial skin infections (8.1% vs. 6.6%), skin inflammation (7.4% vs. 5.8%), and skin masses (5.9% vs. 3.6%). About 3% of dogs showed pain at the injection site, and 3% had episodes of inappropriate urination.
The European trial flagged different patterns. The most notable was elevated blood urea nitrogen, a kidney-related lab value, seen in 13.8% of Librela dogs compared to 4.9% on placebo. However, this elevation wasn’t accompanied by other markers of kidney disease, so its clinical significance remains unclear. Lethargy (3.6% vs. 0%), vomiting (2.9% vs. 0.7%), and loss of appetite (2.2% vs. 0%) were also more frequent in the Librela group.
Post-Approval Safety Concerns
After Librela reached the broader market, the FDA began receiving reports of more serious adverse events that weren’t prominent in the original trials. The agency issued a “Dear Veterinarian” letter flagging these reports, which include:
- Neurological effects: loss of coordination (ataxia), seizures, partial paralysis, problems with body awareness, and full paralysis
- General effects: loss of appetite, lethargy, and inability to stand
- Urinary effects: excessive thirst, increased urination, and incontinence
- Gastrointestinal effects: vomiting and diarrhea
- Musculoskeletal effects: muscle weakness, tremors, and lameness
In some of these cases, death or euthanasia was reported as an outcome. It’s important to understand that post-approval adverse event reports don’t prove the drug caused these problems. Dogs being treated for osteoarthritis are typically older and already at higher risk for neurological conditions and organ decline. Still, the pattern was concerning enough for the FDA to formally alert veterinarians. The FDA noted that it currently lacks the authority to mandate safety-related labeling changes for animal drugs.
What Isn’t Known Yet
Long-term effects beyond nine months of use have not been evaluated. That’s a significant gap, since osteoarthritis is a lifelong condition and many dogs would need ongoing monthly injections for years.
NGF, the protein Librela blocks, isn’t only involved in pain. It plays a role in the heart and blood vessels, and the long-term consequences of suppressing it in dogs with cardiac disease are unknown. In human clinical trials of similar anti-NGF therapies, a small number of patients developed rapidly progressing osteoarthritis, where the joint deteriorated faster than expected. This hasn’t been reported in dogs, but it also hasn’t been specifically studied.
How Librela Compares to NSAIDs
For many years, nonsteroidal anti-inflammatory drugs like meloxicam and carprofen were the only widely used pharmaceutical options for managing arthritis pain in dogs. They’re effective, but they carry well-known risks to the stomach, liver, and kidneys, particularly with long-term use. Dogs on NSAIDs typically need periodic blood work to monitor organ function.
In a head-to-head comparison, more dogs in a meloxicam group reported side effects (primarily gastrointestinal) than dogs receiving Librela. Because monoclonal antibodies are minimally processed by the liver and kidneys, Librela is generally considered a safer option for dogs with existing organ concerns. Some veterinarians use Librela alongside low-dose NSAIDs for dogs with severe pain, though combining therapies should be guided by your vet’s assessment of the individual dog’s health.
What to Expect in Practice
Each visit is quick. Your vet weighs your dog, selects the correct vial, and gives a small injection under the skin. Most dogs tolerate it well. You may notice improvement within the first few weeks, though some dogs take two or three monthly doses to show a clear response. Signs that it’s working include more willingness to walk, easier time getting up from lying down, less stiffness after rest, and more interest in play.
If your dog develops unusual symptoms after an injection, particularly difficulty walking, loss of coordination, seizures, sudden changes in urination, or extreme lethargy, contact your vet promptly. Because the drug stays in the body for about a month, there’s no way to “stop” a dose once it’s been given, which makes early reporting of any concerning changes especially important.